Technical Analysis for HCM - Hutchison China MediTech Limited

Grade Last Price % Change Price Change
grade C 26.19 -4.59% -1.26
HCM closed down 4.59 percent on Friday, February 21, 2020, on approximately normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical HCM trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
20 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.59%
Pocket Pivot Bullish Swing Setup -4.59%
Overbought Stochastic Strength -4.59%
Pocket Pivot Bullish Swing Setup -4.56%
Overbought Stochastic Strength -4.56%
Bearish Engulfing Bearish -4.49%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health oriented consumer products primarily in the People's Republic of China. It operates through three segments: China Healthcare, Drug Research and Development, and Consumer Products. The company manufactures, distributes, and sells over-the-counter, prescription, and health supplements products under the Bai Yun Shan and Shang Yao brands; and offers drug research and development services. It also offers traditional Chinese medicine products in cardiovascular and cold/flu therapeutic areas. In addition, the company develops clinical drug candidates, including HMPL-004 that is in Phase III clinical trials for ulcerative colitis and Crohn's disease; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung, and gastric cancer; and Sulfatinib, a Phase 1b clinical trial product for neuroendocrine tumours, as well as Epitinib for treating non-small cell lung cancer. Further, it offers Theliatinib, a Phase I clinical trial product for the treatment of solid tumours; AZD6094 that is in Phase 1b clinical trial for treating non-small cell lung and gastric cancer; HMPL-523 and HMPL-689, which are preclinical stage products for the treatment of hematological cancers; and HMPL-453 that is in preclinical stage for the treatment of solid tumours. The company also offers organic and natural food, beverage, baby, and beauty care products; and distributes organic and natural products. Hutchison China MediTech Limited has strategic collaborations with multinational pharmaceutical and healthcare companies, including AstraZeneca AB (Publ); Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Nestlé Health Science SA. The company was founded in 2000 and is based in Hong Kong, Hong Kong. Hutchison China MediTech Limited operates as a subsidiary of Hutchison Healthcare Holdings Limited.
Health Healthcare Pharmaceutical Industry Beverage Pharmaceuticals Drug Discovery Pharmaceutical Industry In China Clinical Trial Non Small Cell Lung Cancer Ulcerative Colitis Design Of Experiments Beauty Care Products Crohn's Disease Clinical Trial Product Hematological Cancers Product Testing Preclinical Stage Products Treatment Of Hematological Cancers Gastric Cancer Medicine Products Nursing Research Traditional Chinese Medicine

Is HCM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 32.55
52 Week Low 16.47
Average Volume 234,493
200-Day Moving Average 23.34
50-Day Moving Average 25.90
20-Day Moving Average 26.16
10-Day Moving Average 27.55
Average True Range 1.11
ADX 19.69
+DI 19.83
-DI 24.77
Chandelier Exit (Long, 3 ATRs ) 25.91
Chandelier Exit (Short, 3 ATRs ) 25.81
Upper Bollinger Band 29.45
Lower Bollinger Band 22.88
Percent B (%b) 0.5
BandWidth 25.11
MACD Line 0.46
MACD Signal Line 0.48
MACD Histogram -0.0143
Fundamentals Value
Market Cap 3.18 Billion
Num Shares 121 Million
EPS 0.11
Price-to-Earnings (P/E) Ratio 238.09
Price-to-Sales 15.61
Price-to-Book 19.63
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.85
Resistance 3 (R3) 28.97 28.20 28.40
Resistance 2 (R2) 28.20 27.53 28.14 28.25
Resistance 1 (R1) 27.20 27.11 26.82 27.08 28.11
Pivot Point 26.43 26.43 26.24 26.37 26.43
Support 1 (S1) 25.43 25.76 25.05 25.31 24.27
Support 2 (S2) 24.66 25.34 24.60 24.13
Support 3 (S3) 23.66 24.66 23.98
Support 4 (S4) 23.54